Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.81), $0.33 worse than the analyst estimate of ($0.48). "The Company did not recognize any revenues during the fourth quarter of 2016 or 2015."

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.